Longboard Pharmaceuticals Inc (LBPH)

• $59.21

  $59.31

  $59.31
  

  0.17%

  Downside

  Day's Volatility :0.17%

  Upside

  0.0%

  
• $3.60

  $59.47

  $59.31
  

  93.93%

  Downside

  52 Weeks Volatility :93.95%

  Upside

  0.27%

  

Returns

What analysts predicted

Upside of 9.04%

• FMR Inc

  11.35%

• RA Capital Management, LLC

  8.46%

• Farallon Capital Management, L.L.C.

  7.56%

• Cormorant Asset Management, LLC

  7.17%

• T. Rowe Price Associates, Inc.

  6.45%

• BlackRock Inc

  6.09%

longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.